Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C
    Meeting Abstract

    Sun, L.; Fayette, J.; Salas, S.; Hong, D. S.; Adkins, D.; Dunn, L.; Ciardiello, F.; Cirauqui, B.; William, W. N. Jr; Saba, N. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023
    Meeting Abstract

    Dignam, J. J.; Romitti, P. A.; Yom, S. S.; Feng, F. Y.; Bradley, J. D.; Mehta, M. P.; Bruner, D. W.; Wenzel, J.; Mamounas, E. P.; George, T. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
    Meeting Abstract

    Tsang, E. S.; Shi, Q.; Olive, K. P.; Collisson, E. A.; Dixon, J. G.; Cusnir, M.; Winograd, R.; Botta, G. P.; Wadlow, R. C.; Shergill, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Khawaja, Mrruh; Naqash, A. R.; Schneider, R.; Shastri, A.; Stahl, M.; Moser, J. C.; Karim, N. F. A.; Madanat, Y.; Jonas, B. A.; Stein, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030
    Meeting Abstract

    Marta, G. N.; Chu, X.; Mukhopadhyay, S.; Abramson, V. G.; Brufsky, A.; Stringer-Reasor, E. M.; Dent, S. F.; Traina, T. A.; Carey, L. A.; Rimawi, M. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study
    Meeting Abstract

    Bhave, M. A.; Jhaveri, K. L.; Kaufman, P. A.; Aftimos, P. G.; Lombard, J. M.; Sideras, K.; Im, S. A.; Ma, C. X.; Lee, K. T.; Kim, S. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies
    Meeting Abstract

    Park, Y. H.; Cortes, J.; Modi, S.; Hurvitz, S. A.; Bianchini, G.; Iwata, H.; Shitara, K.; Siena, S.; Goto, Y.; Ku, G. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP)
    Meeting Abstract

    Till, B. G.; Jacobson, C. A.; Palomba, M. L.; Abramson, J. S.; Arnason, J.; Locke, F. L.; Caimi, P. F.; Grover, N. S.; Karmali, R.; Suh, H. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) plus /- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)
    Meeting Abstract

    Pegram, M. D.; Calfa, C.; Chen, C.; CorteĢs Salgado, A.; Heeke, A. L.; Kang, I.; Pistilli, B.; Pohlmann, P. R.; Rugo, H. S.; Saura, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save